Lyrica (pregabalin) + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Postherpetic Neuralgia ( PHN )

Conditions

Postherpetic Neuralgia ( PHN )

Trial Timeline

Dec 1, 2011 → Jan 1, 2014

NCT ID

NCT01455428

About Lyrica (pregabalin) + Placebo

Lyrica (pregabalin) + Placebo is a approved stage product being developed by Pfizer for Postherpetic Neuralgia ( PHN ). The current trial status is completed. This product is registered under clinical trial identifier NCT01455428. Target conditions include Postherpetic Neuralgia ( PHN ).

What happened to similar drugs?

3 of 7 similar drugs in Postherpetic Neuralgia ( PHN ) were approved

Approved (3) Terminated (1) Active (4)

✅QUTENZAAstellas PharmaApproved

🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3

✅Etoricoxib + PlaceboMerckApproved

🔄Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3

🔄pregabalinPfizerPhase 3

✅pregabalinPfizerApproved

🔄HSK16149 20mg BID + HSK16149 40mg BID + Placebo BIDHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01455428	Approved	Completed	Dec 1, 2011	Jan 1, 2014	Postherpetic Neuralgia ( PHN )
NCT00351611	Approved	Completed	Jul 26, 2006	Feb 4, 2020	Epilepsies, Partial

Competing Products

20 competing products in Postherpetic Neuralgia ( PHN )

See all competitors

Product	Company	Stage	Hype Score
QUTENZA	Astellas Pharma	Approved	43
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
MK-8291 + Placebo	Merck	Phase 1	29
Etoricoxib + Placebo	Merck	Approved	39
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
MK0686	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
RN624 + RN624 + Placebo	Pfizer	Phase 2	35
T-62	Pfizer	Phase 2	27
pregabalin + pregabalin/PF-00489791 + Placebo	Pfizer	Phase 2	35
PH-797804 + Placebo	Pfizer	Phase 2	35
Placebo + Pregabalin + Pregabalin + Pregabalin	Pfizer	Phase 3	40
pregabalin	Pfizer	Phase 3	40
pregabalin	Pfizer	Approved	35
T-62 Dose 1 + T-62 Dose 2	Pfizer	Phase 2	27
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID	Haisco Pharmaceutical Group	Phase 3	40
Levetiracetam	UCB	Phase 2	35